title: Rapid disease progression in human immunodeficiency virus type 1-infected seroconverters in India.
abstract: To determine if the early immunological and virological events of HIV infection are unique in a setting with limited access to health care and HIV-1 subtype C infection, we undertook a prospective cohort study to characterize the early natural history of HIV viral load and CD4(+) T lymphocyte counts in individuals with recent HIV seroconversion in India. CD4(+) T lymphocyte counts were prospectively measured for up to 720 days in 46 antiviral drug-naive persons with very early HIV infection, documented by HIV antibody seroconversion. HIV viral RNA levels were measured subsequently on reposited plasma samples from these same time points. The median viral load "set point" for Indian seroconverters was 28,729 RNA copies/ml. The median CD4(+) cell count following acute primary HIV infection was 644 cells/mm(3). Over the first 2 years since primary infection, the annual rate of increase in HIV viral load was +8274 RNA copies/ml/year and the annual decline in CD4 cell count was -120 cells/year. Although the viral "set point" was similar, the median trajectory of increasing viral load in Indian seroconverters was greater than what has been reported in untreated HIV seroconverters in the United States. These data suggest that the more rapid HIV disease progression described in resource-poor settings may be due to very early virological and host events following primary HIV infection. A rapid increase in viral load within the first 2 years after primary infection may have to be considered when applying treatment guidelines for antiretroviral therapy and opportunistic infection prophylaxis.
authors.affiliation: National AIDS Research Institute, Pune, India. sanjaymehendale@yahoo.com
authors.forename: Sanjay M
authors.initials: SM
authors.lastname: Mehendale
authors.forename: Robert C
authors.initials: RC
authors.lastname: Bollinger
authors.forename: Smita S
authors.initials: SS
authors.lastname: Kulkarni
authors.forename: Rebecca Y
authors.initials: RY
authors.lastname: Stallings
authors.forename: Ronald S
authors.initials: RS
authors.lastname: Brookmeyer
authors.forename: Sangita V
authors.initials: SV
authors.lastname: Kulkarni
authors.forename: Anand D
authors.initials: AD
authors.lastname: Divekar
authors.forename: Raman R
authors.initials: RR
authors.lastname: Gangakhedkar
authors.forename: Smita N
authors.initials: SN
authors.lastname: Joshi
authors.forename: Arun R
authors.initials: AR
authors.lastname: Risbud
authors.forename: Madhuri A
authors.initials: MA
authors.lastname: Thakar
authors.forename: Bharati A
authors.initials: BA
authors.lastname: Mahajan
authors.forename: Varsha A
authors.initials: VA
authors.lastname: Kale
authors.forename: Manisha V
authors.initials: MV
authors.lastname: Ghate
authors.forename: Deepak A
authors.initials: DA
authors.lastname: Gadkari
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Quinn
authors.forename: Ramesh S
authors.initials: RS
authors.lastname: Paranjape
mesh_terms: D018791:CD4 Lymphocyte Count; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015658:HIV Infections / Q000276:immunology / Q000473:pathology* / Q000821:virology; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D007194:India; D008297:Male; D012367:RNA, Viral / Q000097:blood; D019562:Viral Load
chemical_list: D012367:RNA, Viral